11,000 Patients: At-Home Ketamine Depression Data

Clinical trials tell us whether a treatment can work under controlled conditions. Real-world data tells us whether it actually works in practice. A 2024 study by Mathai et al., published in the Journal of Affective Disorders, provided one of the largest real-world datasets ever published on at-home telehealth ketamine therapy: 11,441 patients treated for depression in their own homes.

The Study at a Glance

Mathai and colleagues analyzed outcomes from a large telehealth ketamine program serving patients with depression across the United States. Patients received sublingual ketamine at home under physician supervision via telehealth, with regular mood assessments using validated instruments like the PHQ-9.

The study's scale is its defining feature. While most ketamine studies involve dozens to hundreds of participants, this dataset encompassed over 11,000 patients, providing statistical power to detect patterns, subgroup differences, and safety signals that smaller studies cannot.

Key Findings

Response Rate: 55.8%

More than half of all patients, 55.8%, met criteria for treatment response, defined as a 50% or greater reduction in depression scores. This response rate is consistent with the clinical trial literature and notably strong considering this was a real-world population that included patients who might have been excluded from clinical trials due to comorbidities, medication use, or other factors.

For context, typical response rates for first-line antidepressants in treatment-resistant populations range from 10% to 30%. A 55.8% response rate in a real-world, at-home setting represents a substantial improvement over these benchmarks.

Adverse Event Rate: 3-4.8%

The safety data was equally notable. Only 3% to 4.8% of patients reported adverse events, and the vast majority of these were mild and transient. The most commonly reported adverse events included:

• Nausea
• Dizziness
• Headache
• Anxiety during sessions
• Dissociation (expected and typically transient)

Serious adverse events were rare. The low adverse event rate in an at-home setting is significant because it addresses one of the primary concerns about moving ketamine therapy outside of clinical settings: that patients will experience problems without immediate in-person medical support.

Additional Findings

• Dose-response relationship: Patients who completed more treatment sessions generally showed greater improvement, supporting the serial dosing approach used by most at-home programs.
• Speed of response: Many patients showed meaningful improvement within the first two weeks of treatment, consistent with ketamine's known rapid-acting profile.
• Broad demographic reach: The telehealth model served patients across diverse geographic and demographic backgrounds, including many in areas with limited access to specialty mental health care.

What This Means for At-Home Ketamine Therapy

Validation of the Telehealth Model

The Mathai et al. study provides large-scale validation that at-home ketamine therapy, delivered via telehealth with physician supervision, produces outcomes comparable to those seen in clinical settings. This is important because the at-home model dramatically expands access. Patients no longer need to live near a ketamine infusion clinic or arrange transportation to and from appointments.

Safety in Practice

The low adverse event rate directly addresses the safety question that has surrounded at-home ketamine therapy since its inception. With proper patient selection, medical supervision, and safety protocols, at-home treatment is demonstrably safe for the vast majority of patients.

Real-World Applicability

Clinical trial populations are carefully selected and closely monitored. Real-world populations are messier: patients have comorbid conditions, take multiple medications, and may not adhere perfectly to treatment protocols. The fact that a 55.8% response rate was achieved in this real-world context speaks to the robustness of ketamine's therapeutic effect.

How Isha Health's Data Compares

Isha Health's own clinical outcomes data shows an 88.8% improvement rate across our patient population. The higher rate likely reflects several factors:

• Integrated treatment model: Isha Health combines ketamine with ongoing physician monitoring and therapeutic support
• Patient engagement: Our treatment protocols emphasize active patient participation in the therapeutic process
• Outcome measurement: Consistent, standardized assessment at defined intervals

Both datasets reinforce the same core finding: at-home ketamine therapy works for a substantial majority of patients.

Addressing Common Concerns

"Is at-home ketamine as effective as in-clinic treatment?" The Mathai et al. data suggests yes. The response rates are comparable to those reported in infusion clinic studies, and the safety profile is favorable.

"What if something goes wrong at home?" The 3-4.8% adverse event rate, with serious events being rare, indicates that with proper protocols, at-home treatment is safe. Programs like Isha Health provide physician oversight, clear safety instructions, and require a support person to be present during sessions.

"Is the sample size reliable?" With over 11,000 patients, this is one of the largest ketamine outcome studies ever published. The statistical power to detect meaningful patterns is substantial.

The Bottom Line

The Mathai et al. study provides the strongest real-world evidence to date that at-home telehealth ketamine therapy is both effective and safe for depression. A 55.8% response rate across 11,441 patients, with adverse events in fewer than 5%, establishes a solid evidence base for the at-home treatment model. For patients who cannot access or prefer not to visit infusion clinics, at-home ketamine therapy is a well-supported option backed by large-scale data.

For more on affordable access, see our affordable ketamine therapy page.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.